Onco Wiki / Drogue

Cisplatin

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDRUG-CISPLATIN
TypeMédicament
Alias
CDDPPlatinolPlatinol-QAde la valeur de référenceЦисплатин
Étatreviewed 2026-04-26 | pending_clinical_signoff
MaladiesDIS-ADRENOCORTICAL-CARCINOMA DIS-BURKITT DIS-CERVICAL DIS-CHOLANGIOCARCINOMA DIS-ESOPHAGEAL DIS-GASTRIC DIS-HNSCC DIS-LARYNGEAL DIS-MCL DIS-MESOTHELIOMA DIS-NPC DIS-NSCLC DIS-PENILE-SCC DIS-SCLC DIS-TESTICULAR-GCT DIS-UROTHELIAL DIS-VULVAR-VAGINAL-SCC
SourcesSRC-ESMO-ESOPHAGEAL-2024 SRC-NCCN-ESOPHAGEAL-2025

Faits sur les drogues

CatégorieAgent alkylant de platine (première génération)
MécanismeSquare-planar platinum(II) coordination complex. After cellular uptake and aquation (Cl displaced by water in low-chloride intracellular environment), the activated species forms intra- and inter-strand DNA cross-links, predominantly 1,2-d(GpG) and 1,2-d(ApG) adducts. These adducts distort the DNA helix, blocking replication and transcription, and trigger apoptosis when not repaired. Resistance mechanisms include enhanced nucleotide excision repair, glutathione detoxification, and reduced cellular uptake (CTR1 transporter). Backbone for esophageal CRT, head-and-neck CRT, NSCLC, gastric (legacy), cervical, ovarian, testicular germ-cell, and bladder.
Dose typiqueEsophageal definitive CRT (cisplatin/5-FU): cisplatin 75 mg/m² IV days 1, 29 + 5-FU 1000 mg/m²/d CIV days 1-4 and 29-32. Head-and-neck CRT: 100 mg/m² IV q21d × 3 cycles (high-dose) or 40 mg/m² weekly with RT. NSCLC (cisplatin/etoposide CRT): 50 mg/m² IV days 1, 8, 29, 36. NSCLC adjuvant (cisplatin/vinorelbine): 80 mg/m² IV day 1 q21d × 4. Testicular BEP: 20 mg/m² IV days 1-5 every 21 d × 3-4 cycles. Cervical CRT: 40 mg/m² IV weekly with RT (typically 5-6 cycles). Gastric (legacy ECF/EOX): 60-80 mg/m² IV q21d (FLOT preferred now). Mandatory hydration: ≥1-2 L NS pre-dose + 1-2 L post; mannitol diuresis or furosemide for high-dose schedules; Mg + K replacement.
Ukraine enregistréeVrai
NSZU rembourséVrai
Ukraine vérifiée pour la dernière fois2026-04-27

Avertissements

Notes

Mandatory hydration ≥3 L pre-dose + 24 h post; Mg / K pre-emptive supplementation. Consider carboplatin substitution for CrCl 50-60 or pre-existing hearing loss. Highly-emetogenic chemotherapy (HEC): ondansetron + dexamethasone + NK1-RA (aprepitant or fosaprepitant) + olanzapine premedication required (NCCN antiemesis v1.2025). Baseline + serial audiometry (esp. pediatric / younger adult patients). Uridine triacetate is NOT an antidote (FU only).

Utilisé par

Indication

Protocole thérapeutique